Search Results - "Flechon, A"

Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study by Oing, C., Oechsle, K., Necchi, A., Loriot, Y., De Giorgi, U., Fléchon, A., Daugaard, G., Fedyanin, M., Faré, E., Bokemeyer, C.

“…Bone metastases (BM) are rare in germ cell tumor (GCT) patients. Systematic data on risk factors, treatment and outcome are largely lacking. A database created…”
Get full text

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer by Fizazi, K, De Bono, J.S, Flechon, A, Heidenreich, A, Voog, E, Davis, N.B, Qi, Ming, Bandekar, R, Vermeulen, J.T, Cornfeld, M, Hudes, G.R

“…Abstract Purpose This open-label phase II trial assessed mitoxantrone/prednisone (M/P) with and without siltuximab (CNTO 328), an anti-interleukin-6 chimeric…”
Get full text

Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group by Guerin, M, Miran, C, Colomba, E, Cabart, M, Herrmann, T, Pericart, S, Maillet, D, Neuzillet, Y, Deleuze, A, Coquan, E, Laramas, M, Thibault, C, Abbar, B, Mesnard, B, Borchiellini, D, Dumont, C, Boughalem, E, Deville, J L, Cancel, M, Saldana, C, Khalil, A, Baciarello, G, Flechon, A, Walz, J, Gravis, G

“…Urachal cancer (UrC) is a rare, non-urothelial malignancy. Its natural history and management are poorly understood. Although localized to the bladder dome,…”
Get full text

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1) by De Santis, M., Wiechno, P.J., Bellmunt, J., Lucas, C., Su, W.-C., Albiges, L., Lin, C.-C., Senkus-Konefka, E., Flechon, A., Mourey, L., Necchi, A., Loidl, W.C., Retz, M.M., Vaissière, N., Culine, S.

“…There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the…”
Get full text

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial by Fizazi, K., Gravis, G., Flechon, A., Geoffrois, L., Chevreau, C., Laguerre, B., Delva, R., Eymard, J.C., Rolland, F., Houede, N., Laplanche, A., Burcoveanu, D., Culine, S.

“…The standard treatment of patients with metastatic germ-cell tumor (GCT) relapsing after first-line chemotherapy is based on a cisplatin and…”
Get full text

Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA) by Necchi, A., Pouessel, D., Leibowitz-Amit, R., Flechon, A., Gupta, S., Barthelemy, P., Maio, M., Zhu, X., Asatiani, E., Serbest, G., Zhen, H., Loriot, Y.

Get full text

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy by Fizazi, K., Ulys, A., Sengeløv, L., Moe, M., Ladoire, S., Thiery-Vuillemin, A., Flechon, A., Guida, A., Bellmunt, J., Climent, M.A., Chowdhury, S., Dumez, H., Matouskova, M., Penel, N., Liutkauskiene, S., Stachurski, L., Sternberg, C.N., Baton, F., Germann, N., Daugaard, G.

“…This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer…”
Get full text

Management of brain metastases from germ cell tumors: a single center experience by Boyle, H J, Jouanneau, E, Droz, J P, Fléchon, A

“…Brain metastases from germ cell tumors (GCT) are rare and treatment has not yet been standardized. The clinical data of men with brain metastases from GCT…”
Get more information

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up by Fizazi, K., Carmel, A., Joly, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J.-F., Baciuchka Palmaro, M., Laguerre, B., Flechon, A., Ravaud, A., Brihoum, M., Culine, S., Le Teuff, G.

Get full text

Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap) by Negrier, S., Rioux-Leclercq, N., Ravaud, A., Gravis, G., Geoffrois, L., Chevreau, C.M., Rolland, F., Blanc, E., Segura-Ferlay, C., Perol, D., Gross Goupil, M., Dermeche, S., Flechon, A., Albiges, L., Escudier, B.

Get full text

2591 Surgical resection of brain metastasis from renal cancer: Is it worth it? The experience of a French Cancer Center by Eberst, L, Flechon, A, Negrier, S, Neidhardt, E.M, Jouanneau, E, Moriceau, G, Boyle, H.J

Get full text

RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results by Petrylak, D.P., Sternberg, C.N., Drakaki, A., de Wit, R., Nishiyama, H., Necchi, A., Castellano, D., Bamias, A., Chi, K.N., van der Heijden, M.S., Matsubara, N., Hussain, S., Flechon, A., Alekseev, B.Y., Yu, E.Y., Walgren, R.A., Russo, F., Zimmermann, A.H., Bell-Mcguinn, K.M., Powles, T.B.

Get full text

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer by Heudel, P., Chabaud, S., Perol, D., Flechon, A., Fayette, J., Combemale, P., Tredan, O., Desseigne, F., de la Fouchardiere, C., Boyle, H., Perol, M., Bachelot, T., Cassier, P., Avrillon, V., Terret, C., Michallet, A.-S., Neidhardt-Berard, E.-M., Nicolas-Virelizier, E., Dufresne, A., Belhabri, A., Brahmi, M., Lebras, L., Nicolini, F., Sarabi, M., Rey, P., Bonneville-Levard, A., Rochefort, P., Provensal, A.-M., Eberst, L., Assaad, S., Swalduz, A., Saintigny, P., Toussaint, P., Guillermin, Y., Castets, M., Coutzac, C., Meeus, P., Dupré, A., Durand, T., Crochet, H., Fervers, B., Gomez, F., Rivoire, M., Gregoire, V., Claude, L., Chassagne-Clement, C., Pilleul, F., Mognetti, T., Russias, B., Soubirou, J.-L., Lasset, C., Chvetzoff, G., Mehlen, P., Beaupère, S., Zrounba, P., Ray-Coquard, I., Blay, J.-Y.

“…Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint…”
Get full text

Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study by Fizazi, K., Oldenburg, J., Dunant, A., Chen, I., Salvioni, R., Hartmann, J. T., De Santis, M., Daugaard, G., Flechon, A., de Giorgi, U., Tjulandin, S., Schmoll, H. J., Bouzy, J., Fossa, S. D., Fromont, G.

“…Background: The purpose of this study was to validate a prognostic index [surgical complete response 1 (sCR1)] in patients with postchemotherapy viable…”
Get full text

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party by Necchi, A, Miceli, R, Bregni, M, Bokemeyer, C, Berger, L A, Oechsle, K, Schumacher, K, Kanfer, E, Bourhis, J H, Massard, C, Laszlo, D, Montoro, J, Flechon, A, Arpaci, F, Secondino, S, Wuchter, P, Dreger, P, Crysandt, M, Worel, N, Kruger, W, Ringhoffer, M, Unal, A, Nagler, A, Campos, A, Wahlin, A, Michieli, M, Sucak, G, Donnini, I, Schots, R, Ifrah, N, Badoglio, M, Martino, M, Raggi, D, Giannatempo, P, Rosti, G, Pedrazzoli, P, Lanza, F

“…Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose…”
Get full text

The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area by PIKETTY, A.-C, FLECHON, A, LAPLANCHE, A, NOUYRIGAT, E, DROZ, J.-P, THEODORE, C, FIZAZI, K

“…The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who receive cisplatin-based…”
Get full text

Non-palpable testicular tumors in adults: A management based on imaging? Issue from the French Urologic Association Genital Cancer committee's edit by Rocher, L, Feretti, L, Camparo, P, Savoie, P H, Morel-Journel, N, Murez, T, Sebe, P, Flechon, A, Méjean, A, Durand, X

“…Help in management of non-palpable testicular tumors. French Urologic Association Genital cancer committee's Edit. To review their characterization at imaging…”
Get more information

2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting by Oudard, S, Angelergues, A, Efstathiou, E, Gonzalez, I, Gyftaki, R, Delanoy, N, Ozguroglu, M, Flechon, A, Guillot, A, Le Moulec, S, Castellano, D, Esteban, E, Munarriz, J, Campos Balea, B, Ardavanis, A, Stefanou, D, Bellmunt, J

Get full text

2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel by Angelergues, A, Bellmunt, J, Efstathiou, E, Gonzalez, I, Gyftaki, R, Delanoy, N, Ozguroglu, M, Flechon, A, Guillot, A, Le Moulec, S, Castellano, D, Esteban, E, Munarriz, J, Campos Balea, B, Ardavanis, A, Stefanou, D, Oudard, S

Get full text

Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses by Pfister, C., Gravis, G., Flechon, A., Soulie, M., Guy, L., Laguerre, B., Mottet, N., Joly, F., Allory, Y., Harter, V., Culine, S.

Get full text